SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
CASAMENTO CHARLES J	Eton Pharmaceuticals, Inc. [ETON]	☑ Director ☐ 10% Owner
(Last) (First) (Middle)	Foreign Trading Symbol	☐ Officer (give title below) ☐ Other (specify below)
C/O ETON PHARMACEUTICALS, INC.	3. Date of Earliest Transaction (Month/Day/Year)	
21925 W. FIELD PARKWAY, SUITE 235	11/10/2026	
(Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
DEERPARK IL 60010-7208		☑ Form filed by One Reporting Person
(City) (State) (Zip)		☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/10/2026		M		12,500	A	$7.31	12,500	D	
Common Stock	11/10/2026		M		27,400	A	$3.58	39,900	D	
Common Stock	11/10/2026		M		19,655	A	$8.61	59,555	D	
Common Stock	11/10/2026		M		21,000	A	$3.78	80,555	D	
Common Stock	11/10/2026		S		6,380	D	$64.3287[5][6]	74,175	D	
Common Stock	11/10/2026		S		14,715	D	$65.3249[5][7]	59,460	D	
Common Stock	11/10/2026		S		22,601	D	$66.2615[5][8]	36,859	D	
Common Stock	11/10/2026		S		33,956	D	$67.1103[5][9]	2,903	D	
Common Stock	11/10/2026		S		2,903	D	$67.8695[5][10]	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	$7.31	11/10/2026		M			12,500	02/20/2019[1]	02/19/2029	Common Stock	12,500	$0	0	D	
Stock Option	$3.58	11/10/2026		M			27,400	03/12/2020[2]	03/11/2030	Common Stock	27,400	$0	0	D	
Stock Option	$8.61	11/10/2026		M			19,655	05/03/2021[3]	05/02/2031	Common Stock	19,655	$0	0	D	
Stock Option	$3.78	11/10/2026		M			21,000	02/07/2022[4]	02/06/2032	Common Stock	21,000	$0	29,000	D	

Explanation of Responses:

1. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020.
2. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021.
3. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.
4. The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023.
5. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
6. The shares were sold in multiple trades at prices ranging from $63.755 to $64.685. The price reported above reflects the weighted average sales price.
7. The shares were sold in multiple trades at prices ranging from $64.76 to $65.74. The price reported above reflects the weighted average sales price.
8. The shares were sold in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sales price.
9. The shares were sold in multiple trades at prices ranging from $66.76 to $67.61. The price reported above reflects the weighted average sales price.
10. The shares were sold in multiple trades at prices ranging from $67.76 to $67.975. The price reported above reflects the weighted average sales price.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

/s/ Judith Matthews 11/10/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.